Applied Across Domains of Symptomatic Discomfort

Paclitaxel-Teva is used in situations involving certain distressing symptoms linked to the underlying condition, providing support that helps ease the overall symptom burden. Its therapeutic use is relevant in conditions characterized by periods of heightened symptoms. The medicine is relevant in conditions associated with acute or disruptive episodes, including those that produce significant symptomatic burden. It is commonly used across domains where additional symptomatic support is needed.

---

Managing Symptom Clusters and Heightened Stress

The medicine may assist with symptom clusters that may become intense or disruptive and is applied when symptoms create noticeable functional strain. It is commonly used when short-term symptomatic assistance is needed, helping patients cope more steadily with difficult episodes.

Quick Fact: Support for Symptom Clusters

Paclitaxel-Teva is considered relevant in clinical contexts marked by increased discomfort or tension and heightened physiological stress, often used during phases when symptoms become more noticeable. It helps with maintaining functional stability during symptomatic periods.

“The medicine helps support the patient during difficult episodes by easing distress.”

The symptomatic relief provided contributes to easing the overall symptom load, especially in situations involving recurrent or episodic manifestations.

Regulatory References

1. NIH DailyMed drug information

Eligibility Profile: Who Can and Cannot Use Paclitaxel-Teva

Official regulatory documents strictly define the patient populations eligible to receive Paclitaxel-Teva, primarily through a set of absolute prohibitions and conditional requirements.

---

Absolute Contraindications (Must Not Use)

Paclitaxel-Teva is absolutely contraindicated and must not be used in the following populations:

• Patients with a history of severe hypersensitivity reaction to paclitaxel or to the excipient polyoxyl 35 castor oil.
• Patients with severe hepatic impairment.
• Patients with a starting Absolute Neutrophil Count (ANC) < 1,500 cells/mm^3 for solid tumor indications.
• Patients who are currently breastfeeding/lactating.

---

Restricted and Non-Recommended Use

• Age: The medicine is not recommended for use in children and adolescents (under 18 years) due to a lack of established safety and efficacy data in the pediatric population.
• Pregnancy: Paclitaxel-Teva can cause fetal harm. Patients who are pregnant or who may become pregnant must be advised to use effective contraception.
• Organ Function: Use is restricted in cases of mild or moderate hepatic impairment, often requiring dose reduction. Insufficient data are available to recommend dosage alterations for patients with severe renal impairment.

Pharmacokinetic Interactions

The active ingredient, paclitaxel, is metabolized primarily by the liver enzymes Cytochrome P450 isoenzymes CYP2C8 and CYP3A4.

Substance Category	Interaction Outcome (Regulatory Description)
CYP2C8 or CYP3A4 Inhibitors	Co-administration may increase the plasma concentration (exposure) of paclitaxel, as these inhibitors reduce the drug's metabolic clearance.
CYP2C8 or CYP3A4 Inducers	Co-administration may alter the pharmacokinetics of paclitaxel.

Pharmacodynamic and Administration Sequencing

When paclitaxel is used in combination with other chemotherapy agents, the administration sequence is critical to manage the overall toxicity profile as defined in official documents:

• Cisplatin: The regulatory labeling mandates that paclitaxel must be administered before cisplatin when given in combination to mitigate the risk of severe myelosuppression and heightened neurotoxicity.
• Doxorubicin: When combined with doxorubicin, an administration sequence is required where paclitaxel is given 24 hours after doxorubicin to manage the risk of increased cardiac toxicity.

Excipient and Population Considerations

The formulation contains ethanol (alcohol), which must be considered for potential additive effects on the central nervous system when co-administered with other CNS-active medicines. Furthermore, patients with severe hepatic impairment may be at an increased risk of toxicity, particularly myelosuppression, which is a key consideration for managing interaction-related risks in this specific population.

How Paclitaxel-Teva Works: Mechanism of Action

Targeting the Cell's Structural Scaffold

The drug functions as a microtubule stabilizer by binding directly to the beta-tubulin subunit. This molecular interaction promotes tubulin polymerization and inhibits the necessary depolymerization (breakdown) of the microtubule network. This targeted interference affects cellular processes reliant on dynamic microtubule instability, such as cell shape changes and migration.

Inducing Mitotic Arrest and Apoptosis

By locking the microtubule structure, the drug prevents the formation of a functional mitotic spindle. This failure causes cells to become arrested during division (mitotic arrest at the G2/M phase). The sustained arrest activates the cell’s internal self-destruction program, known as apoptosis, a cascade often assisted by the drug's effect on anti-apoptotic proteins like Bcl-2. This sequence results in the cellular elimination of highly proliferative cells.

️ Understanding Mechanism Limitations

The intrinsic biological constraints of the mechanism include the ability of some cells to reduce drug concentration via efflux pumps, specifically the P-glycoprotein (ABCB1) transporter. This active transport of Paclitaxel out of the cell demonstrates a key physiological constraint where targeted pathway interference is reduced.

How to Use Paclitaxel-Teva

Paclitaxel-Teva is administered solely through intravenous (IV) infusion in a clinical setting under the supervision of a physician experienced in cancer chemotherapy. This medication is supplied as a concentrate that must be diluted prior to infusion, typically to a concentration between 0.3 and 1.2 mg/mL in compatible solutions like 0.9% Sodium Chloride.

---

Official Dosing and Scheduling

The usage pattern is based on intermittent treatment cycles, most commonly repeated every three weeks. The specific dose is calculated based on the patient's body surface area (mg/m^2) and varies by the indication and whether it is used in combination with other agents, such as cisplatin. Infusion duration is a prescriptive component of the regimen, lasting either 3 hours or 24 hours.

Usage Principle	Procedural Requirement
Pre-treatment Mandate	All patients must receive a specific regimen of premedication (corticosteroids and antihistamines) prior to every infusion.
Administration Equipment	The diluted solution must be passed through in-line filters (leq 0.22 mu m) and administered using non-PVC equipment to maintain stability.
Combination Sequencing	When administered with platinum-based therapy, paclitaxel must be given before the platinum agent.

---

Dose Adjustments and Retreatment

Subsequent courses are strictly dependent on the patient's biological recovery, requiring the absolute neutrophil count (ANC) to be 1,500 cells/mm^3 and the platelet count to be 100,000 cells/mm^3 before retreatment can begin. Dose adjustments, typically a 20% reduction, are prescribed following the occurrence of severe neutropenia or severe peripheral neuropathy, and specific dose modifications are mandated for patients with hepatic impairment.

Paclitaxel-Teva: Recent Clinical Evidence

Paclitaxel is a chemotherapy agent categorized as a taxane, commonly used to manage several types of cancer. Clinical trials and research have established its use in both first-line and subsequent therapy regimens, often in combination with other anti-cancer drugs.

---

Approved Indications and Study Outcomes

Paclitaxel-Teva, the generic formulation of paclitaxel, is approved for use in specific advanced or metastatic cancers, based on evidence from large-scale clinical trials:

• Ovarian Carcinoma: Used for advanced disease, both as first-line therapy (combined with cisplatin) and as subsequent therapy after initial failure.
• Breast Carcinoma: Indicated for the adjuvant treatment of node-positive disease following standard chemotherapy, and for metastatic disease after failure of prior combination therapy (which may include an anthracycline).
• Non-Small Cell Lung Cancer (NSCLC): Employed in combination with cisplatin for the first-line treatment of advanced disease in patients who are not candidates for curative surgery or radiation.
• AIDS-Related Kaposi's Sarcoma (KS): Approved for second-line treatment.

In studies, paclitaxel-based regimens demonstrated improved response rates, longer time to disease progression, and longer overall survival when compared to some standard therapies in specific indications, such as first-line ovarian carcinoma treatment.

---

Ongoing Research and Combination Therapies

Recent research continues to explore paclitaxel's role in combination with novel therapeutic agents to address resistance and potentially improve patient outcomes. For example, a phase IIb trial (AIPAC) investigated combining paclitaxel with an immunotherapy agent, eftilagimod alpha, in women with metastatic, hormone receptor-positive breast cancer after failure of endocrine-based therapies. Findings suggested an improvement in median overall survival in predefined patient subgroups, supporting further investigation of such chemo-immunotherapy approaches.

Key Studies & References

1. Paclitaxel and Cisplatin Compared with Cyclophosphamide and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

Common questions about Paclitaxel-Teva (FAQ)

---

Q: What is the recommended dose for a patient with normal body surface area?

Official regulatory documents indicate that the exact dose of Paclitaxel-Teva is calculated based on a patient's body surface area ( mg/m^2). This dose is not fixed and varies significantly depending on the specific type of cancer being treated and whether it is given with other chemotherapy agents. For this reason, a physician determines the appropriate dose for each treatment cycle, as this information is not fixed.

Q: How is the paclitaxel dose adjusted after a severe side effect?

Regulatory labeling addresses dose adjustments following severe side effects. If a patient experiences severe adverse events, such as severe neutropenia (a very low white blood cell count) or severe peripheral neuropathy, the dose for their next course of treatment may be adjusted downward. The official product information specifies that a 20% dose reduction may be applied for subsequent courses following such events.

Q: What is the active ingredient in Paclitaxel-Teva?

The active ingredient in the medication is paclitaxel. Paclitaxel is the generic name for this drug and is the component responsible for its anti-cancer properties. The 'Teva' portion refers to the manufacturer's specific formulation.

Q: Is the drug used alone or always with other drugs?

Paclitaxel is used in both ways, depending on the cancer type and stage. Official product information indicates it is approved for use in combination with other drugs for certain cancers, such as first-line ovarian carcinoma. However, it is also approved to be used alone (monotherapy) in other cases, such as subsequent therapy for metastatic breast cancer.

Q: Is Paclitaxel-Teva a biosimilar or a generic drug?

Paclitaxel-Teva is classified as a generic drug. Paclitaxel is a small-molecule drug. The Teva formulation is considered a generic equivalent of the innovator paclitaxel product. The term 'biosimilar' is a specific regulatory term that applies only to copies of large-molecule biologic drugs and does not apply here.

Q: What is the specific role of the 0.9% Sodium Chloride solution?

The Paclitaxel-Teva product is provided as a concentrate that must be diluted before it can be administered. The 0.9% Sodium Chloride solution, or saline, is one of the compatible intravenous fluids used by healthcare professionals to perform this dilution. The final diluted solution is prepared for administration to the patient.

Q: What part of the body is most at risk for peripheral neuropathy?

Official safety information for paclitaxel highlights the risk of peripheral neuropathy, which is damage to the nerves outside the brain and spinal cord. These symptoms often involve numbness, tingling, or weakness, primarily affecting the hands and feet. Official information indicates the risk increases with cumulative exposure over time.

Q: What is the difference between 3 hour and 24 hour infusion?

The regulatory documents state that the infusion can be administered over either a 3-hour or a 24-hour period. The duration is chosen by the physician based on the patient's specific treatment plan. Official data suggests that different infusion schedules are associated with differing toxicity profiles. For example, the 24-hour infusion is associated with a higher risk of severe myelosuppression, and the 3-hour infusion with a higher risk of severe neurotoxicity.

How to Store and Dispose of Paclitaxel Concentrate for Solution for Infusion

Storage and disposal instructions for Paclitaxel Concentrate are governed by its regulatory classification as a cytotoxic drug.

Storage Requirements

• Unopened Vials: Store the concentrate at a temperature not exceeding 25 C (77 F). Vials must be kept in the original outer carton to protect from light.
• After Opening: The multi-dose concentrate is stable for up to 28 days when stored at or below 25 C and protected from light.
• Diluted Solution: The solution prepared for infusion must be used immediately. If refrigerated (2 C to 8 C), use within 24 hours.
• Container Restriction: Dilution and storage must use non-PVC plastic bags or glass bottles; contact with plasticized PVC equipment is prohibited.
• Child Safety: Keep this medicine out of the sight and reach of children.

Disposal

Any unused portion, residue, or expired product must be discarded according to the applicable special handling and disposal procedures for cytotoxic drugs.